XBI is trading at $144.89, down 3.26%, amid weakness across biotech.
- A sector update cited rotation away from higher-growth investments during the regular session.
- Moderna fell 10% and IBB fell 2% in morning trading, pointing to broader biotech pressure rather than an XBI-specific announcement.
- Technology selling tied to concerns about AI-related debt and spending, while the S&P 500 and Nasdaq were also reported lower.